EXHIBIT 99.1

Explanation of Responses

(1)	On August 22, 2008, Svizera Holdings BV (“Svizera”)purchased an aggregate of 2000 shares of Series C ConvertibleRedeemablePreferred Stock, par value $0.001 per share (“Series C PreferredStock”) of SynovicsPharmaceuticals, Inc. (the “Company”) and warrants to acquire an aggregate of 1,000,000 shares of the Company’scommon stock, par value $0.001 per share, for an aggregateinvestment of $1,000,000 in the Company.
(2)	The conversion price of the Series C Preferred Stock is subject to adjustmentpursuant to the anti-dilutionprovisions of the Series C Preferred Stock Certificate of Designations,Preferences and Rights filed with the Secretary of State of Nevada on May 9, 2008 (“Series C Certificate of Designation”) .
(3)	The Series C Preferred Stock is mandatorilyredeemable by the Company on the third anniversary of the originalissuance date.
(4)	The shares of Series C Preferred Stock are convertible, both at the option of the holder and the Companyaccording to the terms of the Series C Certificate of Designation, at the initial rate of 1,000 shares of common stock for each share of Series C Preferred Stock subject to the anti-dilutionprovisions of the Series C Certificate of Designation.
(5)	The referencedsecurities are owned by Svizera, a wholly-owned subsidiary of ManeeshPharmaceuticals Ltd. (f/k/a ManeeshPharmaceuticals Pvt Ltd) (“Maneesh”) . As directors of Maneesh, the Reporting Person together with his brother, Mr. Vinay Sapte, share the power to vote or to direct the vote or to dispose or direct the disposition of these shares.
(6)	The number of shares issuable upon exercise of the warrants and the exercise price thereof is subject to adjustmentpursuant to the terms of the anti-dilutionprovisions of the Common Stock PurchaseWarrant to be issued to Svizera.